BTG2019 AGENDA

The registration fee to attend this conference includes three days of scientific sessions, workshops, lunch sessions, coffee breaks and corporate mini symposiums. 
DAY 1: MARCH 15, 2019
3rd Floor, Gulangyu Islet Hall

2:00 PM SESSION I: THROMBOSIS AND ITP
Session Chair: Surapol Issaragrisil, Xiao Jun Huang, Zhijan Xiao
1. Treatment of Thrombotic/ Bleeding Complications
Yu Hu
2. Managing Myefibrosis after Ruxolitinib Failure
Hari Parmeswaran

Session Chair: Raymond Wong, Jumin Li, Jun Peng
3. Current standard therapy of ITP
Raymond Wong
4. Novel therapy options for ITP 
Ming Hou

3:20 PM COFFEE/ TEA BREAK

​3:30 PM SESSION II: APLASTIC ANEMIA
Moderator: Hari Parmeswaran, Xin Wang, Mei Zhang
1. Differential Diagnosis of Aplastic Anemia and Bone Marrow Failure Syndromes
Pei Lin
2. Newly diagnosed Aplastic Anemia
Pankaj Malhotra
3. Updates on Transplant in Aplastic Anemia
Ting Yang

4:30 PM SESSION III: INFECTION
Moderator: Simrit Parmar, Sujun Gao, Xielan Zhao
​1. Current Guidelines for Neutropenic Fever
Jianda Hu
2. Fungal Infections: Prophylaxis and Treatment
Jiong Hu
Moderator: William YK Hwang, Yan Li, Yanhua Su
3. Viral Infection: Surveillance, Preemptive Therapy and Treatment
Govind Babu
​4. Cell Therapy for viral infections
Xiangyu Zhao
DAY 1: MARCH 15, 2019
​​3rd Floor，Zhangzhou Hall

3:00 PM Union Forum in Hematology---Case Panel Discussion

Session I Moderators：Ting Niu，Xin Du，Huo Tan 
1. Development of gene Therapy for Hereditary Hematological Disorders
Lei Zhang
2. Case presentation of Thalassemia
Yajing Xu
Panel Discussion：Zhilin Jia，Ruibin Huang, Zhiling Yan, Jingxin Pan

Session II Moderators：Bo Zheng，Xudong Ma，Jianzhen Shen
1. Case presentation of Myelofibrosis
Yong Wu
2. Case presentation of Refractory ITP
Heng Mei
Panel Discussion：Lijuan Li, Fenge Yang，Huafang Wang, Weimen Chen

Session III Moderators：Zhen Cai ，Hongxia Yao，Xiongpeng Zhu  
1. Diagnosis and Management of poor graft function post-HSCT
Yuqian Sun
2. Case presentation of Infectious Disease
Yi Chen
Panel Discussion：Nainong Li，Quanyi Lu,，Dingming Wan，Hongyu Zhang

Session IV Moderators: Zunmin Zhu，Yinghao Lu，Guangsheng Wu 
1. Case presentation of Indolent Lymphoma with aggressive features
Junling Zhuang
2. Case presentation of Lymphoma
Li Wang
3. Case presentation of CRES and CRS post-CART
Xiaofeng Luo
Panel Discussion：Yang Xu，Congmeng Lin，Ren Lin, ​Junmin Chen
DAY 2: MARCH 16, 2019
3rd Floor, Xiamen Hall

7:00 AM : Poster Mounting

8:00 AM INAUGURATION CEREMONY
​Moderator: Jianda Hu and Simrit Parmar
Speech by: Vice President Wang Xiaomin; Yuanzhong Chen, Surapol Issaragrisil, Xiao Jun Huang,

8:30 AM PLENARY SESSION I: LEUKEMIA 
Moderator: Chen Yuanzhong, Surapol Issaragrisil and Didier Blaise
1. Post-Transplant Strategies for AML/ MDS:
    Includes post-SCT maintenance, NK Cell Therapy. 
​     Xiao Jun Huang 
2. Treatment Advances: Myelodysplastic Syndrome: 
    Includes newly diagnosed and relapsed disease. 
    Pankaj Malhotra
3. AML Treatment in the Current Era
    Includes diagnosis, prognostication, upfront targeted treatment.
​     JianXian Wang
Moderator: Simrit Parmar, Kaiyan Liu, Yu Hu
4.  Diagnosis, Classification and Risk Stratification for Myeloid Malignancies 
     Includes myelodysplastic Syndrome
     Ling Zhang
5. CAR-T Treatment for B-cell ALL with or without Allo-HSCT: Experience from Lu Daopei Hospital
​     Peggy Lu

​10:10 AM: COFFEE BREAK and POSTER VIEWING

10:20 AM PLENARY SESSION II: CAR T CELL THERAPY
Moderator: YL Kwong, Qifa Liu, Jianda Hu
1. Commercial CAR T Cell Therapy
     Overview of the registered trials and clinical outcomes including YESCARTA and KYMRIAH
       Swami Iyer
2. Point-Of-Care CAR T Cell Therapy
    Overview and Application of Hospital based GMP manufactured CART Cell Therapy
    Hari Parmeswaran
3. CART in Asia
    Overview of the progress made in CART Cell Therapy in Asian Sector
    Xiao Jun Huang

11:20 AM PLENARY SESSION III: CELL THERAPY
Moderator: Kailan Xu, Jianfeng Zhou ​, David Ritchie
1. CRS and neurotoxicity
    Toxicity grading and management pearls
    Aibin Liang
2. NK Cell Therapy
    Off the shelf and donor derived NK Cell Therapy
    Didier Blaise

12:20 PM SPECIAL SATELLITE LUNCH SYMPOSIUM
1. NOVARTIS ITP Session
Moderator: Yu Hu，Xiaochuan Bai
Renchi Yang
2. BEIGENE Satellite
Moderator: Xiaojun Huang, Jianda Hu
Weili Zhao
3. Ibrutinib: Current Progress and Beyond
Moderator: Kaiyan Liu
Shenmiao Yang

1:20 PM: KIAN ANG MEMORIAL LECTURE
Moderator: Surapol Issaragrisil and Kaiyan Liu
Topic: Inflammation and Cancer
Simrit Parmar

1:50 PM: COFFEE BREAK and POSTER VIEWING

DAY 2: MARCH 16, 2019 
PLENARY SESSION
3rd Floor，Xiamen Hall
​
2:00 PM PLENARY SESSION IV: LYMPHOMA 
Moderator: Adolfo de la Fuente, William YK Hwang, Juan Li
1. T-cell Lymphoma: Are we getting closer to improved outcomes?:
    Discuss the different subtypes, specific regimens, approval of Mogamulizumab  for CTCL and MF, role of Brentuximab.
    YL Kwong
2. Hodgkins Lymphoma: from remission to cure?:
    Includes new data on Brentuximab incorporation into newly diagnosed HL as well as role of PD1 inhibitors in relapsed disease, role of AlloSCT.
    Swami Iyer
3. Relapsed NHL: Has CART cell therapy the new standard for salvage?:
    Discuss bridging vs. definitive therapy with CART and also the role of auto and allo-SCT in relapsed disease.
    David Ritchie
Moderator: Hari Parmeswaran, Zhizhe Chen, Swami Iyer
4. Next-Generation Hematopoeitic Stem cell Transplantation (HSCT): Incorporating Immune and Stem Cell Expansion"
Induction regimens beyond R-CHOP in Non Hodgkin's Lymphoma:
William YK Hwang
5. Induction regimens beyond R-CHOP in Non-Hodgkin's Lymphoma
    Discuss Bendamustine based regimens and the upfront Lenalidomide, R-EPOCH in different subtypes of NHL.
    Ashok Vaid
6. Monitoring for a response in Lymphoma:
    Discuss role of PET scan, after how many cycles, optimal response, change in therapy, follow up scans​.
    Weili Zhao
​
4:00 PM COFFEE BREAK and POSTER VIEWING

4:10 PM PLENARY SESSION V: MULTIPLE MYELOMA
Moderator: Didier Blaise, Jingwen Wang, Wei Li
​1. Optimal Induction therapy for newly diagnosed myeloma:
    Do we have a consensus? Discuss the doublet, triplet, quadruplet therapies. 
    Robert Orlowski
2. Post induction treatment strategy:
    AutoSCT vs consolidation. Role of maintenance and monitoring
    Swami Iyer
Moderator: Robert Orlowski, Xi Zhang, Jing Liu
3. Relapsed myeloma: Role of immunotherapy:
    BiTE and CARTs and antibody based therapy
    David Ritchie
4. Bone disease in Myeloma:
    Update on treatment and prevention
    Jin Lu
5:30 PM JANSSEN VELCADE SATELLITE SYMPOSIUM
Moderator: Jian Hou
Weijun Fu

6:30 PM ADJOURN
GALA DINNER
DAY 2: MARCH 16, 2019
Union Forum on Hematology - Recent Updates
3rd Floor，Gulangyu Islet Hall

Moderators：Hui Liu, Mingzhe Han，Baoan Chen  
Post ASH highlight: Acute Myeloid Leukemia
Yongqian Jia
Post ASH highlight: Hodgkin Lymphoma
Bing Xu

Moderators：Yizhuo Zhang，Xinan Cen，Rong Zhan
Post ASH highlight: Non-Hodgkin Lymphoma
Zhao Wang
Post ASH highlight: Chronic Lymphocytic Lymphoma
Wei Zhang

Satellite Symposium
Moderator: Weili Zhao，Jieping Chen
Danhui Fu 

Moderators：Jianmin Luo，Yingmin Liang，Shaoyuan Wang
Post ASH highlight: GVHD management
Yi Luo
Post ASH highlight: Hodgkin's Lymphoma
Bing Xu

Moderators：Li Liu，Hongguo Zhao, Lin Liu
Post ASH highlight: Multiple Myeloma
Jian Hou
Post ASH highlight: Elderly Acute Myeloid Leukemia
Hao Jiang
DAY 3: MARCH 17, 2019
3rd Floor, Xiamen Hall

8:00 AM PLENARY SESSION I: TRANSPLANTATION
Moderator: Swami Iyer, Song Yongping, Xiao Jun Huang 
1. Haplo vs Cord Transplant: Is the winner clear?
    Discusses the data of comparison of the 2 alternate donor transplant.
    Govind Babu
2. AlloSCT in CR1 for AML:
    Patient stratification, treatment outcomes. 
   Daihong Liu
3. AlloSCT in the era of immunotherapies: Discuss the complications of of prior exposure to checkpoint inhibitors, CARTs,           
    Inotuzumab, increased risk of VOD.
    Didier Blaise
Moderator: Ashok Vaid, Ming Jiang, Yanqin Han
4. CAR-T Cell Therapy for Relapsed/ Refractory B Cell Malignancies
     He Huang
5. Post-Allogeneic strategies:
    Discuss cell therapy, maintenance therapies, monitoring, tapering of immune-suppression.
    Hari Parmeswaran
9:40 AM FUSUN Pharma Satellite Session
Moderator: He Huang
Wenbin Qian

10:00 AM COFFEE BREAK

​10:10 AM: PLENARY SESSION II: GRAFT VS. HOST DISEASE SESSION
​This workshop will provide latest update about treatment strategies for GVHD 
Moderator: Pankaj Malhotra, Yongrong Lai, Jianping Shen
1. Diagnosing, staging, grading
    Includes hyper-acute GVHD and relapsed GVHD vs. chronic GVHD
    Pei Lin
2. GVHD Prevention Strategy 
    Include post-SCT Cy, ATG, Tregs, Immunesuppression
    Didier Blaise
Moderator: Govind Babu, Liping Su, Liangming Ma
3. Treatment: Acute GVHD
    High dose Steroids and Beyond!
    Yu Wang
4. Treatment: Chronic GVHD
    Includes Quality of life outcomes
    Adolfo de la Fuente

1​1:30 AM CLOSING